Note: Ingredients listed on restricted chemical lists
EC/CAS
63-42-3
Name of the chemical
Lactose C12H22O11
Concentration
N/A
EC/CAS
77-92-9
Name of the chemical
Citric acid
Concentration
N/A
EC/CAS
1310-73-2
Name of the chemical
sodium hydroxide
Concentration
N/A
EC/CAS
7732-18-5
Name of the chemical
Water, distilled, conductivity or of similar purity H2O
Concentration
N/A
General Information
Version
04/14/2020
Revision date
2020-04-14
Product name
Micafungin Sodium for Injection, 100 mg/vial
Product name
Micafungin Sodium for Injection, 100 mg/vial
Identification on the label/Trade name
Micafungin Sodium for Injection, 100 mg/vial | Manufacturer Gland Pharma Limited
Manufacturer Name
Gland Pharma Limited
Emergency telephone
+91-40-30510999
Icons in SDS
Company Information
company name
Gland Pharma Limited
GHS Information
Signal word
Not applicable
Section 2
Signal word
Not applicable.
Hazard statements
Not applicable.
Precautionary statements
Not applicable. Emergency Overview This product is intended for therapeutic use only when prescribed by a physician. Potential adverse reactions from prescribed doses and overdoses are described in the package insert.
Principle Routes of Exposure
Inhalation Ingestion Eye contact Skin Absorption. Injection.
Potential health effects
Eye Skin Inhalation Occupational exposure has not been fully investigated. Contact with eyes may cause irritation. May cause skin irritation. May cause irritation of respiratory tract. Ingestion: Signs/Symptoms May cause irritation. Potential adverse reactions from prescribed doses and overdoses are described in the package insert. Occupational exposure has not been fully investigated. Aggravation of Pre-Existing Individuals with hypernatremia or fluid retention. Solutions containing sodium ions should be used with Conditions great care, if at all, in patients with congestive heart failure, severe renal insufficiency and in clinical states in which there exists edema with sodium retention. Solutions that contain acetate ions should be used with great care in patients with metabolic or respiratory alkalosis and hepatic insufficiency.
